Acute Respiratory Distress Syndrome
Acute Respiratory Distress Syndrome Market

Acute Respiratory Distress Syndrome


Acute respiratory distress syndrome (ARDS) is a rapidly progressive disease occurring in critically ill patients. The major complication in ARDS is marked by fluid leakage into the lungs, making breathing difficult or impossible.

Acute lung injury (ALI) is a common condition characterized by acute severe hypoxia that is not due to left atrial hypertension. The term ALI encompasses a continuum of clinical and radiographic changes that affect the lungs, with acute respiratory distress syndrome (ARDS) representing the more severe end of this continuum. 


Acute Respiratory Distress Syndrome Epidemiology Segmentation in the 7MM


  • Total Incident Population of Acute Respiratory Distress Syndrome (ARDS)
  • Severity-specific Incident Population of Acute Respiratory Distress Syndrome (ARDS)
  • Incident Population of Acute Respiratory Distress Syndrome (ARDS) by risk factors


Acute Respiratory Distress Syndrome Epidemiological Insights Observed in the 7MM (2021)


  • The total incident cases of Acute Respiratory Distress Syndrome observed in the 7MM were observed to be 1.1 million in the year 2021. 
  • The highest number of incident cases of Acute Respiratory Distress Syndrome in 7MM was observed in the US, i.e., 634K cases. Whereas the lowest was discovered in Japan, i.e., 73K cases. 
  • Total incident cases in EU5 were found to be approximately 480K cases. 
  • Severity-specific Incident Population of Acute Respiratory Distress Syndrome in the US was found to be 190K (mild), 295K (moderate), and 148K (severe). 


Acute Respiratory Distress Syndrome Market Insight


The market size of Acute Respiratory Distress Syndrome in the 7MM was found to be approximately USD 1,260 million in 2021.  

Acute Respiratory Distress Syndrome Market Strengths

Premium-price agents such as stem cell therapies and other pipeline candidates with a better clinical profile are expected to dominate the ARDS market.

Acute Respiratory Distress Syndrome Market Opportunities

The rise in the incidence of ARSD stimulates the research and development of the drug, as it is likely to provide an appropriate environment for newer products to be profitable.


Acute Respiratory Distress Syndrome Emerging Drugs


The emerging drugs in the Acute Respiratory Distress Syndrome market are

  •       EB05
  • ●      Alteplase (Actilyse)
  • ●      Lucinactant (Sinapultide (KL4) Surfactant)
  • ●      BIO-11006
  • ●      MultiStem (HLCM051)
  • ●      RLF-100 (Zyesami/Aviptadil)
  •   ExoFlo (DB-001)
  •   Traumakine
  • Solnatide (AP301)
  • Cholecalciferol
  • BDB-001
  • Zavegepant/Vazegepant
  • Metablok (LSALT peptide)
  • Lenzilumab
  • Veru-111
  • Human immunoglobulin
  •   Remestemcel-L
  • PLX-PAD
  • CERC-002
  • TD-0903
  •   ILT101 and others


Acute Respiratory Distress Syndrome Key Players 


The key players working in the Acute Respiratory Distress Syndrome market are


  • Edesa Biotech
  • Boehringer Ingelheim
  • Genentech
  • Windtree Therapeutics
  • BioMarck Pharmaceuticals
  • Athersys
  • NeuroRx
  • Relief Therapeutics
  • Direct Biologics
  • Faron Pharmaceuticals
  • APEPTICO Forschung und Entwicklung GmbH
  • Mylan Laboratories
  • Arch Biopartners
  •  Staidson (Beijing) Biopharmaceuticals
  • Biohaven Pharmaceutical
  • Humanigen
  • Laboratoire français de Fractionnement et de Biotechnologies (LFB)
  • Mesoblast Limited
  • Veru
  • Pluristem Therapeutics
  • Cerecor
  • Theravance Biopharma
  • ILTOO Pharma and others